Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gd-BOPTA/Dimeg: experimental disease imaging.

F Cavagna1, M Daprà, F Maggioni

  • 1Research and Development Division, Bracco Industria Chimica SpA, Milan, Italy.

Magnetic Resonance in Medicine
|December 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort.

European journal of neurology·2019
Same author

Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients.

Current oncology (Toronto, Ont.)·2019
Same author

Does Ocular Neuropathic Pain Deserve an Autonomous Position in the IHS Classification? Clinical and Diagnostic Evidences.

Headache·2017
Same author

Gender differences in migraine.

Acta neuropsychiatrica·2014
Same author

What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies.

Psychological medicine·2014
Same author

Robust constraint on a drifting proton-to-electron mass ratio at z=0.89 from methanol observation at three radio telescopes.

Physical review letters·2014
Same journal

Feasibility and SNR Performance of Hyperpolarized <sup>129</sup>Xe Gas Exchange Imaging Using a Balanced SSFP Sequence.

Magnetic resonance in medicine·2026
Same journal

Multi-Contrast Human Brain CEST MRI at 11.7 T: First In Vivo Demonstration.

Magnetic resonance in medicine·2026
Same journal

Suppression of Oscillation and Ghosting in RF-Spoiled Gradient-Echo-Based Dynamic Imaging.

Magnetic resonance in medicine·2026
Same journal

A Simple, Dynamic Geometric Phantom for MRI and CT Reconstruction Pipelines: Beyond Shepp-Logan.

Magnetic resonance in medicine·2026
Same journal

7T 3D-EPI PCASL With High SNR Efficiency and Robustness to Through-Plane B<sub>0</sub> Field Gradients.

Magnetic resonance in medicine·2026
Same journal

A Comparison of Tissue Property Values Estimated Using Conventional Cardiac MRF and MT-Cardiac MRF.

Magnetic resonance in medicine·2026
See all related articles

Gd-BOPTA/Dimeg, a novel MRI contrast agent, significantly improves tumor detection and myocardial imaging in rats. It offers persistent, high contrast enhancement for liver lesions and heart tissue compared to standard agents.

Area of Science:

  • Magnetic Resonance Imaging (MRI)
  • Medical Imaging
  • Pharmacology

Background:

  • Contrast agents are crucial for enhancing image quality in MRI.
  • Existing agents like Gd-DTPA/Dimeg have limitations in specificity and duration.
  • Novel agents are needed for improved detection of focal liver disease and myocardial ischemia.

Purpose of the Study:

  • To evaluate the efficacy of the novel tissue-specific contrast agent, Gd-BOPTA/Dimeg.
  • To assess its performance in MR imaging of experimental focal liver disease and acute myocardial ischemia in rats.
  • To compare Gd-BOPTA/Dimeg with Gd-DTPA/Dimeg.

Main Methods:

  • Utilized experimental models of focal liver disease (implanted liver tumors, blood-borne metastases) and acute myocardial ischemia (coronary artery occlusion) in rats.

Related Experiment Videos

  • Administered Gd-BOPTA/Dimeg at a dose of 250 mumol/kg.
  • Analyzed contrast-to-noise ratio (CNR) and signal intensity changes in tumor, liver parenchyma, and myocardium.
  • Compared results with Gd-DTPA/Dimeg.

    • Main Results:

    • Gd-BOPTA/Dimeg demonstrated a 370% persistent increase in tumor-liver CNR (>2 hours) due to selective enhancement of normal liver parenchyma.
    • Blood-borne metastases showed late CNR enhancement, with some exhibiting early contrast loss.
    • In myocardial imaging, Gd-BOPTA/Dimeg produced stronger and more persistent signal enhancement in normal myocardium and injured areas compared to Gd-DTPA/Dimeg.

    Conclusions:

    • Gd-BOPTA/Dimeg is a highly effective tissue-specific contrast agent for MR imaging.
    • It offers significant improvements in detecting focal liver disease and assessing myocardial ischemia.
    • Its enhanced and persistent signal characteristics make it a promising agent for clinical applications.